Cardiovascular Burden of Narcolepsy Disease (CV-BOND): a real-world evidence study
SLEEP · 11.10.2023 · 46 (10)
DOI: 10.1093/sleep/zsad161 ↗Kurz gefasst
Fachartikel in der Zeitschrift SLEEP, online erschienen am 12.06.2023. Verfasst von Rami H Ben-Joseph und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jazz Pharmaceuticals, Palo Alto, CA, USA. Hauptthemen laut MEDLINE: Narcolepsy, Cardiovascular Diseases. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jazz Pharmaceuticals.
Abstract (Originalsprache)
Study Objectives Narcolepsy is associated with cardiovascular risk factors; however, the risk of new-onset cardiovascular events in this population is unknown. This real-world study evaluated the excess risk of new-onset cardiovascular events in U.S. adults with narcolepsy.
Methods
A retrospective cohort study using IBM MarketScan administrative claims data (2014–2019) was conducted. A narcolepsy cohort, comprising adults (≥18 years) with at least two outpatient claims containing a narcolepsy diagnosis, of which at least one was non-diagnostic, was matched to a non-narcolepsy control cohort (1:3) based on cohort entry date, age, sex, geographic region, and insurance type. The relative risk of new-onset cardiovascular events was estimated using a multivariable Cox proportional hazards model to compute adjusted hazard ratios (HRs) and 95% confidence intervals (CIs).
Results
The narcolepsy and matched non-narcolepsy control cohorts included 12 816 and 38 441 individuals, respectively. At baseline, cohort demographics were generally similar; however, patients with narcolepsy had more comorbidities. In adjusted analyses, the risk of new-onset cardiovascular events was higher in the narcolepsy cohort compared with the control cohort: any stroke (HR [95% CI], 1.71 [1.24, 2.34]); heart failure (1.35 [1.03, 1.76]); ischemic stroke (1.67 [1.19, 2.34]); major adverse cardiac event (1.45 [1.20, 1.74]); grouped instances of stroke, atrial fibrillation, or edema (1.48 [1.25, 1.74]); and cardiovascular disease (1.30 [1.08, 1.56]).
Conclusion
Individuals with narcolepsy are at increased risk of new-onset cardiovascular events compared with individuals without narcolepsy. Physicians should consider cardiovascular risk in patients with narcolepsy when weighing treatment options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Jazz Pharmaceuticals, Palo Alto, CA, USA.
- Stanford University Center for Sleep Sciences and Medicine, Palo Alto, CA, USA.
- Aetion, Inc., New York, NY, USA.
- Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN, USA.
Förderung
- Jazz Pharmaceuticals
Zitieren
APA
Ben-Joseph, R. H., Saad, R., Black, J., Dabrowski, E. C., Taylor, B., Gallucci, S., & Somers, V. K. (2023). Cardiovascular Burden of Narcolepsy Disease (CV-BOND): a real-world evidence study. SLEEP, 46(10). https://doi.org/10.1093/sleep/zsad161
Vancouver
Ben-Joseph RH, Saad R, Black J, Dabrowski EC, Taylor B, Gallucci S, et al. Cardiovascular Burden of Narcolepsy Disease (CV-BOND): a real-world evidence study. SLEEP. 2023;46(10). doi:10.1093/sleep/zsad161
BibTeX
@article{BenJoseph2023,
author = {Ben-Joseph, Rami H and Saad, Ragy and Black, Jed and Dabrowski, Elizabeth C and Taylor, Ben and Gallucci, Sophia and Somers, Virend K},
title = {Cardiovascular Burden of Narcolepsy Disease (CV-BOND): a real-world evidence study},
journal = {SLEEP},
year = {2023},
volume = {46},
number = {10},
doi = {10.1093/sleep/zsad161}
}
EUVIMED